Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Ages 3-15

• Presence of growth failure indicated by height standard deviation score less than equal to -2

• Body mass index greater than or equal to 25th percentile for height age

• IGF concentration less than or equal to 33rd percentile